拉米夫定联合中成药对慢性乙型肝炎血清HBeAg的影响  

Influence of Chinese Patent Medicines Combined with Lamivudine on Sero-HBeAg in Chronic Hepatitis B Patients

作　　者：何玲[1] 杨诗杰[2] 吴进军[3] 项岚[4] 孙丽[3] 王娜[3] 蔡定彬[3] 苏汝好[3] 

机构地区：[1]广东医学院,广东湛江524023 [2]中国疾病控制中心寄生虫病预防控制所,上海200025 [3]广东医学院附属医院,广东湛江524001 [4]河南省开封市医科所,475000

出　　处：《时珍国医国药》2009年第7期1634-1638,共5页Lishizhen Medicine and Materia Medica Research

基　　金：广东省科技攻关项目(No.A98040)

摘　　要：目的评价拉米夫定联合中成药对慢性乙型肝炎(CHB)患者血清HBeAg的影响。方法按照系统评价的原则制定检索策略,收集符合纳入标准的研究并采集相关信息和Meta分析。结果52篇文献符合纳入标准;11个联合治疗方案、4121名患者纳入研究,拉米夫定联合苦参素治疗CHB疗程为3个月、6个月、12个月时相对危险度分别为2.45,1.97,1.64,95%可信区间分别为(2.12,2.84),(1.70,2.27),(1.43,1.88),联合组与对照组相比均有统计学意义。结论拉米夫定联合苦参素治疗慢性乙型肝炎血清HBeAg转阴率的疗效有优于单用拉米夫定的趋势。其他联合治疗方案由于样本例数少而无法得出结论。Objective To estimate the influence of Chinese patent medicines combined with lamivudine on Sero - HBeAg in chronic hepatitis B patiehts. Methods Search strategy was formulated according to the Cochrane systematic review, related information of the literatures met inclusion criteria was gathered. Results 52 trials met the inclusioncriteria, 11 sorts of traditional chinese medicine, 11 sorts of treatment prescription ,4 121 patients were included. Statistical significance between the two groups was identified after treatment for 3 months,6 months, 12 months [ relative risk 2.45,1.97,1.64,95 % confidence interval （ 2.12,2. 84）, （ 1.70,2.27 ）, （ 1.43,1.88 ） respectively ]. Conclusion The therapeutic effect of kushenin combined with lamivudine for chronic hepatitis B on Sero - HBeAg is superior to that of Lamivudine alone. As for other joint programms with only a few samples we could not reach a conclusion.

关 键 词：苦参素 中成药 拉米夫定 慢性乙型肝炎 血清HBEAG META分析 

分 类 号：R285.5[医药卫生—中药学]